Market Cap 70.82M
Revenue (ttm) 80,000.00
Net Income (ttm) -32.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -41,125.00%
Debt to Equity Ratio 0.00
Volume 164,100
Avg Vol 64,288
Day's Range N/A - N/A
Shares Out 38.60M
Stochastic %K 23%
Beta 1.01
Analysts Strong Sell
Price Target $5.00

Company Profile

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive...

Industry: Medical Devices
Sector: Healthcare
Phone: 801 990 0520
Fax: 801 990 6601
Address:
2749 East Parleys Way, Suite 200, Salt Lake City, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 5:43 PM
$SERA RSI: 28.04, MACD: -0.2051 Vol: 0.19, MA20: 2.06, MA50: 2.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
mikesterz7
mikesterz7 Mar. 18 at 8:23 PM
$SERA 🚨 In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women, was published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine. Key findings from the Study include: 56% and 32% fewer babies were born before 32 and 35 weeks, respectively 20% fewer babies admitted to the NICU Fewer health complications for newborns (20% reduction in odds of neonatal morbidity) A NICU day was saved for every 4.2 patients screened Advanced discussions underway with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption, including the addition of a new partner program, bringing the total to two active partner programs. "2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution," said Zhenya Lindgardt, Sera's President and Chief Executive Officer.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 18 at 8:13 PM
$SERA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 36.00% YoY • Reported revenue of $0.01M down -58.33% YoY • Sera Prognostics anticipates continued net losses and negative cash flows for the foreseeable future, but expects its cash runway to last through 2028. Research and development expenses are projected to decrease in 2026, while selling and marketing expenses are expected to increase.
0 · Reply
Fettenajs2026
Fettenajs2026 Mar. 18 at 6:11 PM
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 1:17 PM
Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 11:39 AM
Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD
0 · Reply
prismmarketview
prismmarketview Mar. 11 at 4:45 PM
PRISM Mid-Day Movers: Beauty & Wellness and Pharmaceuticals are Today’s Leaders. The Beachbody Company (NASDAQ: $BODI) is jumping ~32% to $11 on quadruple‑normal volume as traders lean into its cost‑cut turnaround and higher‑margin digital fitness and nutrition subscriptions. KALA BIO (NASDAQ: $KALA) rips 28% to ~$0.38 on an eye‑popping 246M shares traded, a purely momentum‑driven bounce that still leaves this sub‑$10M, loss‑making biotech deep in penny‑stock territory. Other Notable Movers: Ocugen, Inc. ( $OCGN) up 26% Sera Prognostics ( $SERA) up 25% Wearable Devices Ltd. ( $WLDS) down -17% https://prismmarketview.com/prism-mid-day-movers-beauty-wellness-and-pharmaceuticals-are-todays-leaders/
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 4:47 PM
$SERA Current Stock Price: $2.57 Contracts to trade: $2.5 SERA Feb 20 2026 Call Entry: $0.27 Exit: $0.41 ROI: 52% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 25 at 1:20 AM
$SERA RSI: 56.78, MACD: 0.0441 Vol: 0.26, MA20: 3.37, MA50: 3.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DARKP00L
DARKP00L Jan. 7 at 1:55 PM
$SERA 08:40 on Jan. 07 2026 Sera Prognostics Announces Randomized Trial Finds PreTRM Test Improves Outcomes By Identifying Women At Risk For Preterm Birth #tradeideas
0 · Reply
Latest News on SERA
Sera Announces Publication Acceptance for PRIME Study

Nov 24, 2025, 8:00 AM EST - 4 months ago

Sera Announces Publication Acceptance for PRIME Study


Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:11 PM EST - 4 months ago

Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript


SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Nov 13, 2025, 4:05 PM EST - 4 months ago

SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS


Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

Oct 1, 2025, 8:05 AM EDT - 6 months ago

Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer


Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:38 AM EDT - 8 months ago

Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript


SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Aug 6, 2025, 4:05 PM EDT - 8 months ago

SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS


SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

May 29, 2025, 8:30 AM EDT - 10 months ago

SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES


SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

May 14, 2025, 4:05 PM EDT - 11 months ago

SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE


Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Transcript

May 11, 2025, 5:35 AM EDT - 11 months ago

Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Transcript


SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

May 7, 2025, 4:05 PM EDT - 11 months ago

SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS


Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 7:13 PM EDT - 1 year ago

Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript


Sera Prognostics Announces Proposed Public Offering

Feb 10, 2025, 4:01 PM EST - 1 year ago

Sera Prognostics Announces Proposed Public Offering


Sera Prognostics to Host Virtual R&D Day on January 31

Jan 27, 2025, 5:02 PM EST - 1 year ago

Sera Prognostics to Host Virtual R&D Day on January 31


Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 9:46 AM EST - 1 year ago

Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript


Sera Prognostics, Inc. (SERA) Q1 2024 Earnings Call Transcript

May 8, 2024, 11:10 PM EDT - 2 years ago

Sera Prognostics, Inc. (SERA) Q1 2024 Earnings Call Transcript


SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

May 8, 2024, 4:05 PM EDT - 2 years ago

SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS


Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

Mar 24, 2024, 2:15 AM EDT - 2 years ago

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health


Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 9:53 PM EDT - 2 years ago

Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript


SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

Mar 20, 2024, 4:05 PM EDT - 2 years ago

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS


OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 5:43 PM
$SERA RSI: 28.04, MACD: -0.2051 Vol: 0.19, MA20: 2.06, MA50: 2.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
mikesterz7
mikesterz7 Mar. 18 at 8:23 PM
$SERA 🚨 In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women, was published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine. Key findings from the Study include: 56% and 32% fewer babies were born before 32 and 35 weeks, respectively 20% fewer babies admitted to the NICU Fewer health complications for newborns (20% reduction in odds of neonatal morbidity) A NICU day was saved for every 4.2 patients screened Advanced discussions underway with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption, including the addition of a new partner program, bringing the total to two active partner programs. "2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution," said Zhenya Lindgardt, Sera's President and Chief Executive Officer.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 18 at 8:13 PM
$SERA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 36.00% YoY • Reported revenue of $0.01M down -58.33% YoY • Sera Prognostics anticipates continued net losses and negative cash flows for the foreseeable future, but expects its cash runway to last through 2028. Research and development expenses are projected to decrease in 2026, while selling and marketing expenses are expected to increase.
0 · Reply
Fettenajs2026
Fettenajs2026 Mar. 18 at 6:11 PM
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 1:17 PM
Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 11:39 AM
Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD
0 · Reply
prismmarketview
prismmarketview Mar. 11 at 4:45 PM
PRISM Mid-Day Movers: Beauty & Wellness and Pharmaceuticals are Today’s Leaders. The Beachbody Company (NASDAQ: $BODI) is jumping ~32% to $11 on quadruple‑normal volume as traders lean into its cost‑cut turnaround and higher‑margin digital fitness and nutrition subscriptions. KALA BIO (NASDAQ: $KALA) rips 28% to ~$0.38 on an eye‑popping 246M shares traded, a purely momentum‑driven bounce that still leaves this sub‑$10M, loss‑making biotech deep in penny‑stock territory. Other Notable Movers: Ocugen, Inc. ( $OCGN) up 26% Sera Prognostics ( $SERA) up 25% Wearable Devices Ltd. ( $WLDS) down -17% https://prismmarketview.com/prism-mid-day-movers-beauty-wellness-and-pharmaceuticals-are-todays-leaders/
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 4:47 PM
$SERA Current Stock Price: $2.57 Contracts to trade: $2.5 SERA Feb 20 2026 Call Entry: $0.27 Exit: $0.41 ROI: 52% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 25 at 1:20 AM
$SERA RSI: 56.78, MACD: 0.0441 Vol: 0.26, MA20: 3.37, MA50: 3.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DARKP00L
DARKP00L Jan. 7 at 1:55 PM
$SERA 08:40 on Jan. 07 2026 Sera Prognostics Announces Randomized Trial Finds PreTRM Test Improves Outcomes By Identifying Women At Risk For Preterm Birth #tradeideas
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 5:28 PM
$SERA RSI: 76.84, MACD: 0.1233 Vol: 0.24, MA20: 3.35, MA50: 3.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CalypsoCalls
CalypsoCalls Dec. 25 at 8:48 AM
$SERA Strategic positioning matters less than consistent throughput, because growth without leverage now attracts skepticism. Absent traction, patience will erode.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 23 at 10:02 PM
$SERA Share Price: $3.59 Contract Selected: Jan 15, 2027 $2.5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.43 – $1.75 Potential Upside: 59% ROI Time to Expiration: 387 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
notreload_ai
notreload_ai Dec. 15 at 4:13 PM
Jefferies starts coverage of $SERA with a Buy rating, highlighting its PreTRM test for predicting preterm birth and $1.6B U.S. market potential. https://notreload.xyz/jefferies-gives-buy-rating-to-sera-prognostics/
0 · Reply
quodo
quodo Dec. 15 at 2:25 PM
$SMTI $CMMB $SERA $NTHI Most small caps are still trying to survive 2026. $CAPS is already planning how to compound through it. $100M run-rate reaffirmed. Margins expanding. Execution > speculation.
0 · Reply
Goldwave9
Goldwave9 Nov. 27 at 4:19 PM
$SERA this will be a big big mover, but not necessarily in five minutes. Give it some time.
0 · Reply
d_risk
d_risk Nov. 13 at 10:08 PM
$SERA - Sera Prognostics Inc. Class A Common Stock - 10Q - Updated Risk Factors SERA’s latest 10-Q risk factors spotlight new dependencies on third-party specimen collection, expanded cost and capital needs, heightened PreTRM test commercialization hurdles, major elaboration on supply chain, cybersecurity, and AI risks, removal of data privacy and healthcare compliance disclosures, and added warnings on analyst coverage, anti-takeover provisions, and exclusive forum clauses—reflecting broader operational, financial, and regulatory uncertainties. #HealthcareDiagnostics #RegulatoryCompliance #AIRisk #Cybersecurity #SupplyChainRisk 🟢 Added 🟠 Removed https://d-risk.ai/SERA/10-Q/2025-11-13
0 · Reply
kshonstocks
kshonstocks Oct. 27 at 2:23 PM
$SERA from scans, has the higher highs
0 · Reply
MilsLearning
MilsLearning Oct. 10 at 5:19 PM
$SERA Ever get bullied??? Trading stocks?? Me too!!! Well 🖕🩳🖕🩳🖕🩳🔥🔥🩳🔥🩳🔥
0 · Reply
WallStJoey
WallStJoey Oct. 7 at 11:13 AM
watch PRHI Traders always look after the run. s giving every early signal now. 98 short squeeze score, micro float, no borrow, golden cross forming. And nobody’s loading? This is the type of setup that makes careers... $GENE $BTTX $MBRX $XELA $SERA
0 · Reply